zepbound 10mg/0.5ml

Zepbound (tirzepatide) 10 mg/0.5 mL – Complete Guide
🔹 Key Details

Dosage: 10 mg per 0.5 mL (4th step in titration, after 2.5 mg → 5 mg → 7.5 mg).

Administration: Subcutaneous (under skin) once weekly via pre-filled auto-injector.

FDA Approval: For chronic weight management in adults with:

BMI ≥30 kg/m² (obesity) OR

BMI ≥27 kg/m² + weight-related condition (e.g., hypertension, type 2 diabetes).

🔹 Dosing Schedule

Weeks
Dose
Purpose

1–4
2.5 mg
Starter (minimizes side effects)

5–8
5 mg
Initial therapeutic dose

9–12
7.5 mg
Intermediate dose

13+
10 mg
Higher efficacy (may increase further to 12.5 mg or 15 mg if needed)

Note: Some patients stay at 10 mg if achieving sufficient weight loss with minimal side effects.

🔹 Effectiveness

Clinical Trial Data (SURMOUNT-1):

10 mg dose: Average weight loss of ~18–21% over 72 weeks (with diet/exercise).

15 mg dose: Up to 22.5% weight loss (highest dose).

Comparison to Wegovy (semaglutide):

Zepbound (dual GLP-1/GIP agonist) may lead to ~2–5% greater weight loss than Wegovy (GLP-1 only).

🔹 Side Effects

Common (≥10%)
Less Common (1–10%)
Rare but Serious

Nausea, diarrhea, constipation, vomiting
Fatigue, dizziness, heartburn
Pancreatitis, gallbladder disease, kidney inj